JP2022040131A5 - - Google Patents

Download PDF

Info

Publication number
JP2022040131A5
JP2022040131A5 JP2021202636A JP2021202636A JP2022040131A5 JP 2022040131 A5 JP2022040131 A5 JP 2022040131A5 JP 2021202636 A JP2021202636 A JP 2021202636A JP 2021202636 A JP2021202636 A JP 2021202636A JP 2022040131 A5 JP2022040131 A5 JP 2022040131A5
Authority
JP
Japan
Prior art keywords
formula
cpp
alkyl
compound
ceremony
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021202636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022040131A (ja
Filing date
Publication date
Priority claimed from JP2017535019A external-priority patent/JP6994941B2/ja
Application filed filed Critical
Publication of JP2022040131A publication Critical patent/JP2022040131A/ja
Publication of JP2022040131A5 publication Critical patent/JP2022040131A5/ja
Withdrawn legal-status Critical Current

Links

JP2021202636A 2014-12-31 2021-12-14 アンチセンス抗細菌性化合物および方法 Withdrawn JP2022040131A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462098713P 2014-12-31 2014-12-31
US62/098,713 2014-12-31
JP2017535019A JP6994941B2 (ja) 2014-12-31 2015-12-23 アンチセンス抗細菌性化合物および方法
PCT/US2015/000280 WO2016108930A2 (en) 2014-12-31 2015-12-23 Antisense antibacterial compounds and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017535019A Division JP6994941B2 (ja) 2014-12-31 2015-12-23 アンチセンス抗細菌性化合物および方法

Publications (2)

Publication Number Publication Date
JP2022040131A JP2022040131A (ja) 2022-03-10
JP2022040131A5 true JP2022040131A5 (enExample) 2022-07-07

Family

ID=56285129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017535019A Active JP6994941B2 (ja) 2014-12-31 2015-12-23 アンチセンス抗細菌性化合物および方法
JP2021202636A Withdrawn JP2022040131A (ja) 2014-12-31 2021-12-14 アンチセンス抗細菌性化合物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017535019A Active JP6994941B2 (ja) 2014-12-31 2015-12-23 アンチセンス抗細菌性化合物および方法

Country Status (7)

Country Link
US (1) US11293024B2 (enExample)
EP (1) EP3240794A4 (enExample)
JP (2) JP6994941B2 (enExample)
AU (1) AU2015372560B2 (enExample)
CA (2) CA3249464A1 (enExample)
HK (1) HK1246303A1 (enExample)
WO (1) WO2016108930A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
EP3569252B1 (en) 2014-05-19 2021-12-15 Oregon State University Antisense antibacterial compounds and methods
CA3249464A1 (en) 2014-12-31 2025-11-29 Univ Texas Antisense antibacterial compounds and methods
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
JP7393121B2 (ja) 2015-12-23 2023-12-06 オレゴン ステイト ユニバーシティー アンチセンス抗菌化合物および方法
WO2020035620A1 (en) * 2018-08-17 2020-02-20 Centre National De La Recherche Scientifique (Cnrs) Rna-based therapeutic methods to protect animals against pathogenic bacteria and / or promote beneficial effects of symbiotic and commensal bacteria
GB2579253A (en) 2018-11-28 2020-06-17 Pedanius Therapeutics Ltd Antibacterial antisense agents

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668616A (en) * 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
PT876165E (pt) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
AU7327598A (en) * 1997-05-02 1998-11-27 University Of Guelph Proteins involved in the synthesis and assembly of core lipopolysaccharide of pseudomonas aeruginosa
WO2000015265A1 (en) 1998-09-16 2000-03-23 Vitagenix, Inc. Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
US20040033972A1 (en) * 2000-12-20 2004-02-19 Horwitz Marcus A. Treatment of mycobacterium tuberculosis with antisense polynucleotides
US20060241075A1 (en) 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1620112A4 (en) 2003-04-17 2007-04-25 Univ Columbia DESMOGLEIN 4 IS A NEW GENUS INVOLVED IN HAIR GROWTH
EP1629105B1 (en) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
CA2571593C (en) 2004-07-02 2015-04-21 Avi Biopharma, Inc. Antisense antibacterial method and compound
US20060263798A1 (en) 2005-02-11 2006-11-23 International Business Machines Corporation System and method for identification of MicroRNA precursor sequences and corresponding mature MicroRNA sequences from genomic sequences
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
CA2614191C (en) 2005-07-13 2015-06-30 Avi Biopharma, Inc. Antisense antibacterial method and compound
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
WO2007025016A1 (en) 2005-08-25 2007-03-01 Texas Tech University System Inhibition of metallo-beta-lactamase by double-stranded dna
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
DK2207779T3 (da) 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2009139635A1 (en) * 2008-05-15 2009-11-19 Prosensa Technologies B.V. Polymyxin derivatives and uses thereof
WO2010134939A2 (en) * 2008-12-19 2010-11-25 Zirus, Inc. Mammalian genes involved in infection
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011018798A2 (en) * 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
DK2623507T3 (da) 2010-09-30 2017-01-02 Nippon Shinyaku Co Ltd Morpholinonukleinsyrederivat
EP2638161A1 (en) * 2010-11-12 2013-09-18 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
US20120213663A1 (en) 2011-02-23 2012-08-23 King Fahd University Of Petroleum And Minerals Method of removing e. coli bacteria from an aqueous solution
IL273838B (en) 2011-05-05 2022-09-01 Sarepta Therapeutics Inc Peptide and oligonucleotide conjugates, preparations containing them and their uses
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR101317263B1 (ko) 2011-07-05 2013-10-10 (주)지노첵 리얼타임 pcr을 이용한 카바페넴 내성 장내균 검사 방법 및 키트
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
JP2015500204A (ja) 2011-11-18 2015-01-05 サレプタ セラピューティクス, インコーポレイテッド 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
KR101450751B1 (ko) * 2012-07-05 2014-10-16 서강대학교산학협력단 미생물을 이용한 지방산 제조 방법
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
EP3569252B1 (en) 2014-05-19 2021-12-15 Oregon State University Antisense antibacterial compounds and methods
CA3249464A1 (en) 2014-12-31 2025-11-29 Univ Texas Antisense antibacterial compounds and methods
US10907158B2 (en) 2015-12-23 2021-02-02 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
JP7393121B2 (ja) 2015-12-23 2023-12-06 オレゴン ステイト ユニバーシティー アンチセンス抗菌化合物および方法

Similar Documents

Publication Publication Date Title
US12414961B2 (en) Substituted nucleosides and nucleotides for treating viral infections
JP6814127B2 (ja) 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット
AU2021202224A1 (en) Peptide oligonucleotide conjugates
JP2022512975A (ja) S-抗原輸送阻害オリゴヌクレオチドポリマーおよび方法
RU2015100198A (ru) Хиральный адъювант нуклеиновой кислоты
JP2019511491A5 (enExample)
US10202602B2 (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
CN107148424A (zh) 用于诱导细胞因子的环状二核苷酸
RU2011127079A (ru) Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с
JP2018506272A5 (enExample)
KR20080059612A (ko) 5-아자-시토신이 내부에 삽입된 올리고뉴클레오티드 유사체
JP2010510301A (ja) 化合物
RU2012121264A (ru) Терапевтические пептиды
JPS6144820A (ja) 遺伝子発現の選択的阻害剤
JP2022536495A5 (enExample)
JP2014500230A5 (enExample)
JP2005525991A5 (enExample)
US11192914B2 (en) Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190085013A1 (en) Nucleotide and nucleoside therapeutic compositions and uses related thereto
EP3143038A1 (de) Peptid-nukleinsäuren-monomere und -oligomere
CN110573620B (zh) 血癌治疗剂
HUP0105310A2 (en) Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections
US20250262315A1 (en) Tripeptide linkers and methods of use thereof
JP2024537711A5 (enExample)
US20250289843A1 (en) Process for preparation of targeting ligands